特科罗在研创新药启动临床一期Ib(MAD)雄激素性脱发人体抗病毒

Tolerability, and Pharmacokinetics of TDM-105795 in Healthy Male Subjects with Androgenetic Alopecia”. Study objectives are to evaluate the safety and pharmacokinetics of topical TDM-105795 following repeated doses. Two U.S. clinical sites are currently participating in this study.

Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We also expect the current study results to guide choice of formulation strength(s) appropriate for a subsequent proof-of-concept (PoC) Phase 2 Androgenetic Alopecia study. The Company anticipates the robust induction of hair growth demonstrated by TDM-105795 in preclinical testing should be observable within several months of initiating treatment.”

“We look to the TDM-105795 AGA program as the first clinical anchor among our pipeline products for treatment of various dermatologic diseases,” said Zengquan Wang, Chief Executive Officer at Technoderma Medicines. “We are working to bring a second pipeline product (Atopic Dermatitis) into clinical testing soon in mid-year.”

。

绥化白癜风最好医院
鹤岗白癜风哪里治疗好
榆林治白癜风哪里最好
类风湿关节炎特效药
咳嗽有痰黄痰怎么回事啊
英夫利昔（西）单抗
牙痛有什么办法止痛
脂肪肝中药配方